Herb Mueller
Analyst · JPMorgan. Your line is now open
Thank you, Kate and good afternoon everyone. I’ll start by giving detail on our fiscal third quarter financial results, and will then discuss the early trends we’re seeing in the fourth quarter. I’ll also give further detail on the financial impact of the strategic growth initiatives and recent acquisitions that Kate discussed. Starting with an overview of our third quarter results. Total revenue for the third quarter of fiscal 2018 was $172.4 million, a 20% increase from the comparable quarter a year ago, including our acquisitions, and up 5% excluding them. Sequentially, revenue was up 10%. On a constant currency basis, revenue increased 17.6% year over year and 9.6% sequentially. Our third quarter gross margin was 36.3%, flat compared to the prior year third quarter. SG&A expenses were $55.3 million or 32.1% of revenue, compared to $45.4 million, 31.5% of revenue in the fiscal third quarter a year ago. I’ll provide more color on SG&A shortly. Our net income was $4.6 million or $0.14 per diluted share. In quarter three, adjusted EBITDA was $8.7 million or 5% of revenue, compared to $8.4 million or 5.8% of revenue in the year ago quarter. Now let me discuss some of the highlights of our revenues geographically. As Kate mentioned, we had strong revenue growth across the board. For the third quarter, total revenues internationally were approximately $38.1 million versus $26.9 million in the third quarter a year ago, an increase of 41.4% year over year, 29.6% constant currency, and an increase of 2.1% sequentially, 0.6% constant currency. These results were bolstered by our strong performance in both Europe and Asia Pacific. Europe showed improvement for the ninth successive quarter, reporting revenue growth of about 34% year over year, excluding revenue from taskforce and flat sequentially, even though there were two additional holidays in the third quarter compared to the second quarter. Asia Pacific reported strong revenue, up 9.4% year over year and flat sequentially. Our US performance strengthened in the quarter, with revenue increasing 14.9% year over year, including Accretive. These results reflect increased activity overall, higher bill rates in several of the company's largest markets, and also reflects our continued progress on our strategic initiatives and the integration of Accretive. Sequentially, revenue in the US increased approximately 12.5%, including our acquisitions. Excluding acquisitions, revenue sequentially decreased slightly at 2%. A normal trend since this quarter includes the Christmas, New Year’s holidays. Turning to the revenue trends for the fourth quarter of fiscal 2018. Weekly revenues in Q4 are trending approximately 22.5% ahead of last year, including taskforce and Accretive. If the current trend continues, revenue would be in the range of $178 million to $182 million overall compared to $148.6 million a year ago. Without Accretive and taskforce, the revenue trend is $156 million to $160 million. The high end of the range is based on the current trend of 7.5% organic growth. As we continue the integration of Accretive in the fourth quarter, we will lose the ability to break it out from overall RGP results. Turning to gross margins. Including our acquisitions, gross margin for the third quarter was 36.3%, flat compared to the prior year third quarter, and decreasing 160 basis points sequentially. The sequential decrease is related primarily to the normal resetting of employer payroll tax obligations at the beginning of a new calendar year, and a slight increase in pay rate per hour. Excluding reimbursable expenses, our third quarter gross margin was 36.9%, which compares to 37% in the third quarter a year ago. For the third quarter, our gross margin in the US was 36.9%, the same as last year's third quarter mark. And our international gross margin improved to 34%, compared to 33.8% a year ago. For the court quarter, we expect our gross margin to be in the 38% to 39% range, compared to 39.1% a year ago. The year over year decrease is primarily a result of pressure on pay rates, the growth of our international business, as well as the two acquisitions having slightly lower gross margins. The average hourly bill rate for the quarter, including acquisitions, was approximately $123, which compares to $123, including acquisitions in the second quarter and $118 in the year ago quarter. The average pay rate for the third quarter was approximately $63, compared to $59 last year, and $61 last quarter. As a reminder, these hourly rates are derived based on prevailing exchange rates during each given period. Now to headcount. Quarter end consulting headcount was three 3,143, including 402 from Accretive, and 48 from taskforce, versus 2,611 a year ago. The total headcount of the company, including Accretive and taskforce, was 4,033 at quarter end. While overall headcount increased, we will remain diligent in our efforts to ensure we have the right level of personnel in the right markets. For instance, we've added talent in Europe to support their growth. Now looking at other components of our third quarter financial results. SG&A expenses were $55.3 million or 32.1% of revenue. This compares to SG&A of $45.4 million or 31.5% of revenue in the third quarter of fiscal 2017, and $47.5 million or 30.3% of revenue in the second quarter of fiscal 2018. Our SG&A also includes non-cash charges for stock compensation expense of $1.4 million or 0.8% of total revenue. The year over year increase of $9.9 million from last year's third quarter, relates largely to costs associated with the SG&A of the taskforce and Accretive operations, integration costs associated with the acquisitions, and increased business development efforts. Specifically, SG&A includes $6.2 million directly from the acquired businesses, $0.7 million from severance, $2.9 million from integration of the acquisitions, and the ongoing efforts to transform our sales and business development efforts. The combined impact of these charges were $0.11 per diluted share on (stage) results. In addition, the increase over our estimated range for the quarter included medical claims that were approximately $350,000 higher than normal. We also booked an additional $300,000 of bad debt reserve due to higher AR levels and a currency hit of $1 million compared to last year, primarily relating to the strengthening of the Euro, Yen and Pound in the quarter. We view the temporary bump in SG&A costs as necessary short term investments in the growth of our business and our client base, and expect that some of these costs will continue into the fourth quarter. We anticipate the bulk of these integration and transformation costs will taper off beginning in fiscal year 2019, and be further offset by additional cost synergies realized with the successful integrations of the Accretive transitions. As Kate discussed earlier, reducing SG&A as a percent of revenue, remains one of our strategic priorities and we're fully committed to improving cost containment efforts within our day to day operating model, and we'll continue to closely monitor SG&A while focusing on growth. In the fourth quarter, we expect SG&A to be in the range of $54.5 million to $55.5 million, approximately 31% of sales, which will include $2.5 million to $3 million of spending for the transformation and integration of the acquisitions. This includes cost for consultants and training related activities. We recognize that these costs are a little higher than we previously outlined, but our goal is to ensure that the integration and transformation is extremely successful. The resulting growth we are currently achieving supports our decisions. At the end of the third quarter, our office count was 74, 48 domestic and 26 international. During the third quarter, we added five offices in the US as a result of our acquisition of Accretive. Turning to the other components of our financial statements. Deprecation was just over $1 million, compared to approximately $950,000 in the second quarter. Amortization expense was $1 million, compared to $300,000 in the second quarter, as a result of the additional amortization of intangibles relating to Accretive. Our adjusted EBITDA cash flow margin, which we define as EBITDA before stock compensation, was 5% in the third quarter, down slightly from 5.8% a year ago, and 8.5% in the second quarter of fiscal 2018. Our pretax income was $4.6 million in the third quarter. During the quarter, we recorded a provision for income taxes of $46,000, representing an effective tax rate of 1%. The drop in tax expense this quarter relates to the revaluing of our deferred tax assets and liabilities as required by the Tax Cuts and Jobs Act of approximately $1.1 million and additional $1.1 million related to bringing our overall tax expense into line with the new US mandated lower rate. The favorable impact on EPS in the quarter for these changes was $0.07 per share. For the fourth quarter, lower tax rate will continue to reduce the US tax rate by approximately 5%. We will also incur a write off of deferred tax assets of approximately $1.4 million related to the expiration of unexercised stock options. Also note that our GAAP tax rate for each of the upcoming quarters is difficult to predict, and could be volatile as the rate will be dependent on several factors, including the operating results of our US and foreign locations, each of which are taxed or benefited at different statutory rates, and the offset of the tax benefit of foreign losses in certain locations by valuation allowances. On a cash basis, our tax rate was about 36%, and we expect that rate to decrease going forward. We do not expect any charges on our accumulated offshore earnings. Finally, our GAAP net income was approximately $4.6 million or $0.14 per share during the third quarter. Now let me turn to the balance sheet. Cash and investments at the end of the third quarter were $43.2 million, a $13.1 million decrease from the second quarter of fiscal 2018. This was primarily a result of the Accretive acquisition, share buybacks during the quarter, interim bonus payments during the quarter, and the settlement of payroll obligations on the last working day of the quarter. Receivables at quarter end were approximately $126 million, compared to approximately $109 million at the end of the second quarter. The increase of $17 million is split between approximately $10 million of new receivables from former Accretive clients and growth in our core business. Days of revenue outstanding were approximately 65 days compared to 63 days in the second quarter of fiscal 2018. Dividends for the quarter totaled proximately $3.7 million. Capital expenditures were $836,000 during the quarter, net of landlord reimbursements. In the third quarter, we repurchased approximately 321,000 shares at an average stock price of $15.95 per share for approximately $5.1 million. Our stock buyback program has $120 million remaining. We will continue to return cash to shareholders through our quarterly dividend, while balancing debt repayment, the capital requirements of our growing business, organically and inorganically, and fiscal prudence. Our shares outstanding at the end of the third quarter were approximately 31.5 million. We issued 1,072,000 shares (indiscernible) third quarter related to the Accretive acquisition. Now turning to the financial impacts of our Accretive and taskforce acquisitions. As Kate mentioned, the integration of our taskforce acquisition is substantially complete. We're also nearing completion of our integration of Accretive. As Kate and I both mentioned earlier, the acquisitions have already begun to have a positive impact on our results, including taskforce revenue of approximately $3.8 million and EBITDA of $700,000, and Accretive revenue of approximately $17.3 million and EBITDA of $1.1 million. We’ve already achieved over half of the cost reductions we expected to realize from these acquisitions, including $500,000 in back office cost reductions attributable to Accretive. We’re on track to complete the balance of the cost reductions by the first quarter of FY’19, and expect to have both acquisitions fully integrated at that time. We’re excited about our acquisition of Accretive and taskforce, and we're continuing to work to identify additional growth opportunities, both inorganic and organic. And finally, I’d like to discuss the financial impacts of the strategic initiatives that Kate covered earlier. As a reminder, we first outlined these three initiatives just one year ago, with specific goals to reduce costs over time, enhance our revenue and improve our operating model. We said we expected to take 18 months, and we've been able to accelerate the timeline, though with that, we increased our cost in the short term. However, this will allow us to see the overall benefits earlier than originally expected. We continue to successfully implement these initiatives, and are pleased with the progress we made in the third quarter, in particular with the sales transformation initiative and the redesign of our business model. Our revenue enhancement we continue to believe that initially as we've outlined, will put us in a stronger financial position going forward, and we're already seeing growth. As Kate mentioned earlier, in the US, our sales transformation is largely complete. We have achieved all but one of the objectives we initially outlined for this initiative. We have completed the rollout of sales force throughout the company and now have developed go to market, sales management and account development playbooks. We've also launched a new learning and development program. Our new incentive compensation structure for our sales team is still under development, but we expect to have that completed by the end of Q4 for implementation in FY’19. Revenue for our strategic client program is up 9% year over year and trending positively. We expect to complete substantially all of our sales transformation by the end of the fiscal year, and we're now working to refine all of the sales initiatives that we've implemented over the last 12 months to ensure we're optimizing our efforts. With regards to the redesign of the business model, this quarter we finished building out our talent group, marking the completion of all of our major structural updates. We’re now fully - operating fully under the new organizational design in the US, and we're focusing on driving accountability and productivity across all positions. We expect these efforts to continue to improve efficiencies across the company. While we discussed our cost containment initiative earlier in the call, I want to reiterate that we remain committed to lowering SG&A as a percentage of revenue over the last several years. Despite some onetime expenses related primarily to severance, our acquisition and our sales transformation and business development costs, we have not lost sight of our cost savings goals. As mentioned earlier, we’ve accelerated the timeline of our initiatives. These efforts have already delivered improved revenue growth, and we expect this upward performance trend to continue throughout fiscal year 2018 and into 2019. Our efforts to executing against our strategic initiatives have already delivered improved revenue growth and have been further supported and enhanced by the client offerings at taskforce and Accretive. As such, we anticipate that this upward performance trend will continue. As Kate discussed earlier, we’re very pleased to see our acquisitions and strategic initiatives beginning to bear fruit. We expect the momentum to continue and anticipate seeing improvement as we finish out the fiscal year. We will now begin to focus - shift our focus to evaluating how our initiatives are performing and finalizing the integrations of our two acquisitions. In summary, we're very excited about - that our transformation and acquisition initiatives are ahead of schedule, and believe that we're set for an exciting FY’19. Now I'd like to turn the call back over Kate to for some closing comments.